Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | TPO | P07202 | 1/20 | 0.42 |
| ▸ | EPX | P11678 | 1/20 | 0.42 |
| ▸ | LPO | P22079 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30222343 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNATDP1CYP19A1 | |
| SCHEMBL2747551 | 0.82 | PDE7A (0.44) | ALDH1A1SMN1; SMN2MPOTPOEPX | |
| SCHEMBL30354782 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNATDP1CYP19A1 | |
| SCHEMBL4796250 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNATDP1CYP19A1 | |
| SCHEMBL5570151 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNATDP1CYP19A1 | |
| SCHEMBL29887935 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNATDP1CYP19A1 | |
| SCHEMBL5593294 | 0.81 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2LMNATDP1CYP19A1 | |
| SCHEMBL1446655 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNATDP1CYP19A1 | |
| SCHEMBL21191106 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNATDP1CYP19A1 | |
| SCHEMBL631854 | 0.80 | PDE7A (0.49) | ALDH1A1SMN1; SMN2LMNAMPOTPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332493-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | OSI PHARMACEUTICALS (US) | 2008-02-19 | — | — | US | claimed |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-07-21 | — | — | US | claimed |
| US-6890924-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2005-05-10 | — | — | US | claimed |
| EP-1292591-B1 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2005-02-02 | — | — | EP | claimed |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER PRODUCTS INC. | 2002-11-14 | — | — | US | claimed |
| WO-2023015240-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-1664029-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-7332493-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | OSI PHARMACEUTICALS (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-07-21 | — | — | US | disclosed |
| US-6890924-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2005026152-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| EP-1292591-B1 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER PRODUCTS INC. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | ALDH1A1 296/4885SMN1; SMN2 1107/4885LMNA 938/4885 |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | ALDH1A1 3334/4885SMN1; SMN2 4731/4885LMNA 3367/4885 |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | ALDH1A1 342/4885SMN1; SMN2 915/4885LMNA 670/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | ALDH1A1 4094/4885SMN1; SMN2 4856/4885LMNA 3726/4885 |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | ERBB2, ERBB3, ERBB4 | ALDH1A1 3782/4885SMN1; SMN2 4594/4885LMNA 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.